IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
A prospective study on the assessment of the quality of life in patients with locally advanced carcinoma cervix preand post-chemo-radiotherapy

Author: NAVANEETHA SUBRAMANIYAN, PRANABANDHU DAS, AMMAGUNTA HARITHA, VARADHA RAVI KISHORE, NAYAB REENAZ, VELAMALA SRILATHA, ANNA BALAJI, BV SUBRAMANIAN
Abstract: The objective of the present work is to explore the quality of life (QoL) among women affected by cervix cancer both before and after treatment with chemoradiotherapy, to investigate various factors influencing the QoLamong this women and to assess the effect of treatment modalities on the QoL. This prospective study covered thirty two newly diagnosed locally advanced carcinoma cervix patients (FIGO IB2-IVA) in the department of radiation oncology, Sri Venkateshwara Institute of Medical Sciences (SVIMS), Tirupati, India. Patients who met inclusion criteria were questioned with the structured questionnaire of QoL i.e European Organization for Research and Treatment of Cancer (EORTC) QLQ30, and its Cervical Cancer Module (Cx24) was employed to assess the QoL before treatment and four months after completion of the planned chemoradiotherapy treatment. Themean global health score,post treatment was 60.48 whereas pre-treatment score of 99.85. This is statistically significantly. Various measured parameters of QoL such as physical, role, emotional, cognitive and social functioning improved significantly (p<0.05) behind the treatment. Loss of appetite, fatigue, nausea, vomiting, pain, constipation, insomnia improved significantly (p<0.05), but no significant improvement observed for dyspnea. There was a significant change in cervical cancer related symptomscore (EORTC QLQ CX-24) such as decrease in burning micturition, sexual activity, and vaginal discharge after treatment which were statically significant. But the painful sexual activity did not change significantly. The Quality of life was improved significantly after using chemo-radiotherapy in newly diagnosed locally advanced carcinoma cervix patients. Improvement was also exhibited on the five functional scales of EORTC QLQ-C30. To facilitate further improvement of QoL, the proper psychological, social assistance and awareness about various self-limiting complications to allay fear and anxiety of the patients may be needed.
Keyword: locally advanced carcinoma cervix, quality of life,chemo-radiotherapy
DOI: https://doi.org/10.31838/ijpr/2019.11.04.043
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
Pharmacovigilance: Current Scenario and Emerging Trends

National Conference sponsored by GUJCOST on 03.08.2019 at SNLPCP, Umrakh

Download Brochure
News & Events
0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus